Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune discovered aducanumab, a human monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease, and licensed it to Biogen.
- http://www.neurimmune.com
- +41 44 755 46 23
- fabian.buller@neurimmune.com